Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Aug;30(4):1063-1070. doi: 10.19746/j.cnki.issn.1009-2137.2022.04.014.
ABSTRACT
AbstractObjective: To analyze the expression of FOSB in acute myeloid leukemia （AML） and its correlation with prognosis of the patient based on the large sample data.
METHODS: The genome, transcriptome, gene chip and clinical information from multiple public databases were statistical analyzed.
RESULTS: The expression of FOSB gene in AML patients was significantly higher than that in normal people. The prognostic analysis of the 163 patients showed that the patients with high FOSB expression showed longer OS and EFS than those with FOSB low expression. The patients were further divided into chemotherapy group and allogeneic hematopoietic stem cell transplantation (allo-HSCT) group according to the treatment method, and then each group was divided into two subgroups (FOSBhigh, FOSBlow) according to the median expression level of FOSB. In the allo-HSCT group, the patients with FOSB high expression was longer event-free survival (EFS: P=0.017) and overall survival (OS: P=0029). At the same time, allo-HSCT in patients with high FOSB expression could improve the prognosis of the patients (Chemotherapy vs Allo-HSCT, OS: P<0.001, EFS: P=0.007). Multivariate analysis showed that the high expression of FOSB was an independent favorable prognostic factor for EFS and OS (EFS: HR=0.501， P=0.019; OS: HR=0.461， P=0.009) of the patients.
CONCLUSION: The high expression of FOSB indicated a good prognosis for acute myeloid leukemia.
PMID:35981363 | DOI:10.19746/j.cnki.issn.1009-2137.2022.04.014
